In this context, and given the relevance of oxidative stress homeostasis in CML treatment and prognosis, we evaluated the possible association of NFE2L2, KEAP1, SOD2, CAT, and GPX1 genetic variants with TKI response (including the response rates, number of required lines of TKI treatment, and presence of BCR::ABL1 mutations) and disease prognosis (progression and overall survival). The gene discussed is NFE2L2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.